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alvular Heart Disease and Pregnancy
art I: Native Valves
ri Elkayam, MD, FACC, Fahed Bitar, MD
os Angeles, California
Pregnancy in patients with valvular heart disease (VHD) continues to pose a challenge to both
physicians and their patients and could be associated with an unfavorable maternal as well as
fetal outcome. The purpose of this paper is to review the available clinical data and provide
recommendations for the management of patients with VHD during gestation. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.02.085Cardiol 2005;46:223–30) © 2005 by the American College of Cardiology Foundation
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rhe presence of valvular heart disease (VHD) due to both
ongenital and acquired etiologies in a pregnant patient
ontinues to pose a challenge to clinicians and their patients
1,2). This condition increases the risk of pregnancy to both
he mother and the fetus and requires specific care to avoid
r at least minimize maternal morbidity and mortality and
ssure fetal well-being. The goal of this paper is to review
he available information and provide recommendations for
he management of patients with VHD during pregnancy.
ENERAL CONSIDERATIONS
reconception evaluation. The management of women
ith VHD should ideally begin before conception. A
areful cardiac examination and assessment of functional
apacity are needed to determine the likelihood of the
atients to tolerate the increased hemodynamic burden of
regnancy and the risk of complications during gestation.
reconception evaluation, therefore, should include a care-
ul history and physical examination, a 12-lead electrocar-
iogram, an echocardiogram, and a Doppler study. In
atients with a history of impaired or questionable func-
ional capacity, an exercise test, preferably with measure-
ent of oxygen consumption (3), is useful for an objective
ssessment of functional classification. The anticipated risk
f pregnancy on the basis of the evaluation should be
iscussed with the patient and her family by both the
ardiologist and the obstetrician. In anticipation of preg-
ancy, drugs with potential harm to the fetus (4), should be
iscontinued.
ntepartal and peripartal care. Antepartal care should
nclude a joint obstetric and cardiologic evaluation with a
requency on the basis of the type and severity of the disease
s well as the patient condition. In general, antenatal visits
hould be scheduled every month in women with mild
isease and every 2 weeks in women with moderate and
evere disease until 28 to 30 weeks and weekly thereafter
ntil delivery. When drug therapy seems necessary, the
From the Heart Failure Program, Division of Cardiovascular Medicine, UniversityA
f Southern California, Keck School of Medicine, Los Angeles, California.
Manuscript received January 28, 2005, accepted February 8, 2005.mallest therapeutic dose of drugs known to be safe for the
etus should be used (4). In assessing a patient with VHD
uring pregnancy, it should be noted that the evaluation
ay be complicated by normal anatomical and functional
hanges of the cardiovascular system that may result in signs
nd symptoms that can mimic heart disease (5). These
nclude fatigue, decreased exercise capacity, shortness of
reath, palpitations, light-headedness, and even syncope.
hysical examination often reveals increased jugular venous
ulsation, leg edema, palpable right ventricular heave, and a
ystolic murmur (5). Therefore, in many cases it is imper-
tive to use additional diagnostic tools to obtain accurate
nformation about cardiac status before therapeutic deci-
ions are made.
abor and delivery. Timing and mode of delivery should
e discussed and decided upon jointly by the obstetrician,
ardiologist, and obstetric anesthesiologist. In general, vag-
nal delivery with appropriate anesthesia and shortening of
he second stage is safe and can be performed in the majority
f patients with VHD (6,7). Cesarean section is potentially
ssociated with a higher rate of complications (8) and
hould usually be performed for obstetric indications and in
he occasional patient with cardiac instability. Hemody-
amic monitoring during labor and delivery is recom-
ended in symptomatic patients and in patients with
oderate or severe valvular stenosis, left ventricular dys-
unction, and pulmonary hypertension.
arly puerperium. In spite of the blood loss associated
ith delivery, the early puerperium is associated with
ncreased venous return to the heart caused by blood shift
rom the emptied uterus into the systemic circulation,
ecreased caval compression, and mobilization of fluid from
he limbs and lower body (9). These hemodynamic changes
an lead to heart failure (6,7) and require continued hemo-
ynamic monitoring for 12 to 24 h after the delivery.
ntibiotic prophylaxis. Antibiotic prophylaxis has been
ecommended for patients with VHD who undergo manip-
lations or surgical procedures likely to result in bacteremia
10). The use of antibiotic prophylaxis, however, was not
ecommended by the last American Heart Association/
merican College of Cardiology practice guidelines for
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Valvular Heart Disease and Pregnancy July 19, 2005:223–30ncomplicated vaginal or abdominal delivery on the basis of
arly studies indicating a low likelihood for bacteremia
ssociated with these procedures (11,12). Recent reports,
owever, have indicated a higher rate of bacteremia after
abor and delivery. Boggess et al. (13) detected bacteremia in
4% of 93 women after labor or rupture of membranes, and
any of the organisms isolated were capable of causing
ndocarditis. Petanovic and Zagar (14) reported positive
lood cultures in 19% of 235 blood culture samples exam-
ned in women during delivery, and Furman et al. (15)
eported bacteremia in the postpartum in 9.4% of 968
omen with and 5% of 4,692 women without pre-labor
upture of membranes. In a recent review of bacterial
ndocarditis complicating 68 pregnancies, the calculated
aternal and fetal mortality rate was 22% and 15%, respec-
ively (16). Because of this new information indicating a
igher risk of bacteremia even after uncomplicated delivery,
he relative low risk and cost of therapy, and the potential
evastating effect of endocarditis, prophylactic antibiotic
reatment for labor is given routinely in patients with VHD
n many institutions, including ours (17,18). The recom-
ended regimens for antibiotic prophylaxis include ampi-
illin (2.0 g intramuscular [IM] or intravenous [IV]) plus
entamicin (1.5 mg/kg, not to exceed 120 mg) given at
nitiation of labor or within 30 min of a cesarean section,
ollowed by ampicillin (1 g IM or IV) or amoxicillin (1 g
rally) 6 h later. For patients allergic to ampicillin and
moxicillin, vancomycin (1.0 g IV over 1 to 2 h) is
ecommended instead (10).
PECIFIC VALVULAR LESIONS
itral stenosis (MS). Mitral stenosis is the most com-
only encountered valvular lesion in pregnancy (6,7,17,18)
nd is caused in almost all cases by rheumatic heart disease.
lthough rheumatic MS is often accompanied by some
egree of mitral regurgitation (MR) (6,18), pregnancy-
elated hemodynamic and symptomatic problems are pre-
ominantly due to valve stenosis. The pressure gradient
cross the narrowed mitral valve may greatly increase during
regnancy secondary to the physiological rise in heart rate
nd stroke volume, which leads to an increase in left atrial
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
AR  aortic regurgitation
AS  aortic stenosis
IM  intramuscular
IV  intravenous
MR  mitral regurgitation
MS  mitral stenosis
MVA  mitral valve area
NYHA  New York Heart Association
PMBV  percutaneous mitral balloon valvuloplasty
PS  pulmonic stenosisressure and thus to the development or worsening of wymptoms, including dyspnea, decreased exercise capacity,
rthopnea, paroxysmal nocturnal dyspnea, and pulmonary
dema. Increased left atrial pressure can also result in atrial
rrhythmias (6,7), which may lead to a further acceleration
f ventricular rate and thus to additional hemodynamic
orsening and symptomatic deterioration.
ATERNAL RISK. Several reports published in recent years
n pregnancies in women with heart disease have provided
utcome information on over 400 patients with MS in
ifferent parts of the globe (6,7,17–21). Hameed et al. (6)
ublished a case-control study of 46 pregnancies in 44
atients with MS who were compared with a healthy
ontrol group of women matched for age, ethnicity, obstet-
ic and medical history, time of initial prenatal care, and year
f delivery. Twenty-eight of these cases were in the New
ork Heart Association (NYHA) functional class I and 18
ere in class II on their initial clinic visit, and of all 44
atients, 74% demonstrated clinical deterioration during
regnancy. Maternal outcome was favorable in patients with
ild MS and comparable to their control; in contrast, there
as a significantly higher incidence of maternal morbidity in
omen with moderate and severe MS, including the devel-
pment of heart failure, arrhythmias (atrial fibrillation or
upraventricular tachycardia), the need to start and/or in-
rease a dose of cardiac medications, and the need for
ospitalizations.
A later report by Silversides et al. (7) from Canada
escribed the outcome of 80 pregnancies in 74 women with
heumatic MS, which was moderate in 36% and severe in
1% of the cases. Of these pregnancies, 35% were associated
ith maternal cardiac complications, including pulmonary
dema in 31% and arrhythmias in 11%. The first episode of
ulmonary edema occurred in 60% of the patients in the
ntepartum period at a mean gestational age of 30  0.4
eeks, and 20% occurred in the setting of atrial tachyar-
hythmias. Of the nine women who developed arrhythmias
uring pregnancy, 70% had atrial fibrillation and the rest
ad supraventricular tachycardia. The incidence of maternal
omplications was related to the severity of MS and was
7% in women with severe, 38% in those with moderate,
nd 26% in those with mild MS. Barbosa et al. (19) reported
rognostic factors in 41 patients followed in Brazil between
991 and 1999. The risk of maternal events, which included
rogression of heart failure, need for cardiac surgery or
alloon mitral valvuloplasty, death, and thromboembolism,
as strongly associated with the severity of MS and NYHA
unctional class before pregnancy. A strong association
etween patients’ NYHA functional class and both maternal
nd fetal complications was confirmed by Bhatla et al. (18),
ho reported a retrospective analysis in 207 pregnancies in
omen with cardiac disease who delivered28 weeks; 71 of
hese patients had MS.
Despite the high incidence of reported maternal morbid-
ty, maternal mortality associated with pregnancy in patients
ith MS seems to be uncommon. No mortality was re-
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July 19, 2005:223–30 Valvular Heart Disease and Pregnancyorted in 124 pregnancies in women with MS reported by
wo tertiary-care facilities with high-risk obstetric/
ardiology clinics in North America and in 71 cases treated
n a high-volume center in India (6,7,18). Isolated cases of
aternal death have been described in women with critical
S who were in NYHA functional class III and IV in other
eports (16,20).
Although retrospective evaluations reported a low inci-
ence of thromboembolism in patients with MS during
regnancy (17,18), Hameed et al. (22) have recently re-
orted three patients who presented with clinically signifi-
ant left atrial thrombus in the absence of atrial fibrillation
hat resulted in a stroke in one patient and partial occlusion
f the mitral valve orifice leading to worsening of heart
ailure in another patient. The third patient had multiple,
arge left atrial thrombi that were successfully treated with
ow-molecular-weight heparin throughout the pregnancy.
ecause of these findings and the hypercoagulable state of
regnancy, these investigators have recommended strong
onsiderations for anticoagulation prophylaxis during ges-
ation in women with severe MS and enlarged left atrium,
ven in the absence of atrial fibrillation.
ETAL OUTCOME. A comparison of fetal outcome between
omen with MS and a well-matched control group of
ealthy women (6) demonstrated an important effect of MS
n the incidence of preterm delivery (28% [moderate MS]
s. 6% [control] and 44% [severe MS] vs. 11% [control])
nd intrauterine growth retardation (27% [moderate MS]
s. 0% [control] and 33% [severe MS] vs. 0% [control]).
imilarly, there was a substantial impact on birth weight,
hich was reduced from 3,427  426 g in the control
atients to 2,706  1,039 g (p  0.02) in women with
oderate MS and from 3,332  403 g to 2,558  947 g (p
0.05) in cases with severe MS. Birth weight in women
ith mild MS was comparable to their control subjects
3,135 419 g vs. 3,288 531 g). A substantial increase in
ate of premature birth was also reported by Silversides et al.
7). The rate of prematurity was 14% in patients with mild
S, 28% in patients with moderate MS, and 33% in
atients with severe MS.
reatment. The management of MS during gestation is
ore complex because of the potential impact on the fetus
elated to drug therapy and the exposure to ionizing
adiation associated with diagnostic and therapeutic proce-
ures such as cardiac catheterization or percutaneous bal-
oon valvuloplasty, as well as the effect of anesthesia and
ardiopulmonary bypass in the case of cardiac surgery (1).
or clinicians treating women with MS, there are two
eparate groups of patients: the patients with MS who desire
o become pregnant and are being evaluated before preg-
ancy and those who are already pregnant. Patients con-
emplating pregnancy who are found to have severe MS
mitral valve area [MVA] 1.0 cm2) should be offered
ercutaneous mitral balloon valvuloplasty (PMBV) before
regnancy. This approach will minimize or even completely irevent the anticipated clinical deterioration documented in
uch cases (6,7,18) and will reduce the need for pharmaco-
ogic or interventional therapy during pregnancy (18). The
ecision to perform PMBV before conception in patients
ith moderate MS should be on the basis of their MVA,
ymptoms, and exercise tolerance. Careful judgment is
equired in a patient with MS who is not a suitable
andidate for PMBV. In such patients, especially those with
oderate valvular stenosis who are either asymptomatic or
ildly symptomatic, medical therapy during pregnancy may
e preferred to mitral valve replacement before the preg-
ancy. With appropriate follow-up, patients with mild MS
MVA 1.5 cm2) usually have a favorable pregnancy
utcome (6,7); valve repair before pregnancy, therefore, is
ot indicated.
Optimal management of the already pregnant patient
ith MS should aim at reducing the heart rate and left atrial
ressure. Both heart rate and symptoms can be effectively
ontrolled by restricting physical activity and administering
eta-adrenergic receptor blockers (23), which are relatively
afe and, in general, well tolerated by both the mother and
he fetus (24). Use of beta-blockers with beta-1 adrenergic
electivity is preferred, because these agents would be less
ikely to interfere with beta-2–mediated uterine relaxation
24). Metoprolol may be preferred over atenolol, because
he latter may be associated with a higher incidence of fetal
rowth retardation (25). Because of increased sympathetic
ctivity during gestation, higher doses of beta-blockers are
sually needed to achieve heart-rate control compared with
he non-pregnant situation (26). In patients with atrial
brillation, digoxin may also be useful as well as safe for
ontrol of ventricular rate (4). Because of one report
ndicating an increased incidence of major birth defects in
ewborns exposed to diltiazem during the first trimester, the
se of verapamil is preferred when a calcium antagonist is
ndicated for heart-rate control during pregnancy (27). Left
trial pressure can also be reduced by a decrease in blood
olume through restriction of salt intake and the use of oral
iuretics. Aggressive use of diuretics, however, should be
voided to prevent hypovolemia and the reduction of
teroplacental perfusion (28).
ITRAL VALVE REPAIR DURING PREGNANCY. Although
areful follow-up and medical therapy allow successful
ompletion of pregnancy in the great majority of women
6,7,18–21), repair or replacement of the valve during
regnancy may be indicated in selected patients who remain
ymptomatic in spite of adequate medical therapy.
BMV. The use of PBMV during pregnancy has been
eported in an increasing number of patients, with over 300
ases described in recent years (29–37). Most reports
nclude patients at the NYHA functional class III and IV
ho did not respond adequately to pharmacologic therapy.
he procedure was performed in most cases at the end of
he second trimester or the start of the third trimester, and
n the majority of reported cases, hemodynamic and symp-
t
p
a
r
p
c
e
o
p
a
u
s
c
p
s
s
r
d
e
v
E
c
i
d
(
d
p
a
e
f
w
A
m
i
r
p
b
m
h
(
d
i
P
h
l
d
p
t
a
i
d
w
p
l
M
c
w
m
2
c
f
c
o
w
d
s
5
u
m
s
a
f
M
d
d
V
o
w
p
p
r
c
d
f
t
m
w
i
b
E
h
c
a
t
u
v
n
n
m
p
b
I
i
(
(
c
226 Elkayam and Bitar JACC Vol. 46, No. 2, 2005
Valvular Heart Disease and Pregnancy July 19, 2005:223–30omatic improvement was achieved. Mean MVA before the
rocedure ranged from 0.75 to 1.2 cm2 and was increased
fter the procedure to a range of 1.7 to 2.2 cm2. These
esults are similar to the results reported in the non-
regnant patients with MS (38). Reported rate of compli-
ations has been small, but included cardiac tamponade,
xcessive blood loss, transient atrial fibrillation, worsening
f MR, systemic embolization, uterine contractions, and
recipitous labor (29,31,35,39,40). In addition, PBMV is
ssociated with some risk to the fetus secondary to
navoidable ionizing radiation (41). Although recent
tudies have reported normal growth and development of
hildren born to women who underwent PBMV during
regnancy, the number of patients included in these
tudies was small and follow-up was limited to three to
even years (34,42– 44). For this reason and to minimize
isk to the fetus, PBMV should be avoided if possible
uring the first trimester and should be performed by
xperienced operators with adequate abdominal and pel-
ic shielding with minimum radiation exposure (34,37).
xposure can be reduced by minimizing fluoroscopy and
ine time and by using echocardiography and Doppler,
nstead, to obtain information on cardiac function and
egree of MR (37). The use of the Inoue balloon catheter
Toray, Houston, Texas) seems to be preferred over a
ouble-balloon technique, because it takes less time to
erform and thus subjects the fetus to less radiation (45).
Should PBMV be performed prophylactically in
symptomatic or mildly symptomatic women with mod-
rate or severe MS during pregnancy? Recent reports
rom North America have described 126 pregnancies in
omen with MS treated successfully without PBMV.
lthough these pregnancies were associated with no
aternal mortality, a high incidence of maternal morbid-
ty and compromised fetal outcome manifested by growth
etardation, prematurity, and low birth weight was re-
orted (6,7).
Because preterm birth and reduced fetal growth have
een shown to be associated with an increased risk of infant
orbidity and even mortality as well as incidence of adult
ypertension, diabetes mellitus, and cardiovascular disease
46–49), prevention of preterm delivery seems to be a
esirable therapeutic goal. Although some studies have
ndicated improved fetal outcome in women undergoing
BMV during pregnancy (50), other reports described a
igh incidence of prematurity, low birth weight, and fetal
oss (3,32–34,51) in spite of the procedure and suggest that
espite a significant hemodynamic and symptomatic im-
rovement, the performance of PBMV at the second or
hird trimester of pregnancy may not prevent prematurity
nd occasional fetal death. On the basis of the available
nformation, therefore, it seems reasonable to limit PBMV
uring pregnancy to symptomatic patients with severe MS
ho do not respond to medical therapy or who cannot be trovided a close and expert follow-up during pregnancy,
abor and delivery.
ITRAL VALVE SURGERY. A recent review (52) of the out-
ome of cardiovascular surgery in 161 pregnant women, of
hom 59 were operated on for native valve disease, reported
aternal mortality of 9% and fetal or neonatal mortality of
9%. Duration of pregnancy at time of surgery, length of
ardiopulmonary bypass, and temperature did not influence
etal or neonatal outcome. These results have been recently
onfirmed by de Souza et al. (37), who compared the outcome
f 21 patients with severe MS submitted to PMBV and 24
omen who underwent open mitral valve commissurotomy
uring pregnancy and reported 38% fetal mortality in the
urgical group, which occurred up to 24 h after the operation in
of 8 cases. Because of the high risk of what seems to be an
navoidable fetal loss, surgical mitral valve repair or replace-
ent should be considered during pregnancy only in cases with
evere MS who are refractory to optimal medical therapy and
re not suitable candidates for PMBV or in cases where close
ollow-up during pregnancy is not possible.
ODE OF DELIVERY. Hameed et al. (6) reported vaginal
elivery in 92% of 66 pregnancies in patients with VHD
elivered between 1979 and 1998, 46 of whom had MS.
aginal delivery with regional anesthesia was also the mode
f delivery in 74% of cases reported by Silverside et al. (7),
ith assisted delivery in the second stage of labor in 20% of
atients. Cesarean section was performed in 26% of the
regnancies, but only in 1 of 21 cases for maternal cardiac
easons. Similarly, Bhatla et al. (18) reported a 20% rate of
esarean section in a group of 205 patients with cardiac
isease, of whom 71 had MS; cesarean section was per-
ormed in all cases for obstetric indications. This informa-
ion clearly shows that vaginal delivery can be permitted in
ost patients with MS, including those with severe stenosis,
hereas cesarean section is indicated mostly for obstetric
ndications. The second stage of labor should be shortened
y the use of outlet forceps or vacuum extractor (1).
pidural anesthesia is recommended for pain relief (53) and
as been shown to minimize intrapartum fluctuations in
ardiac output (54) and to lower left atrial and pulmonary
rtery pressures (55). Hypotension, the primary complica-
ion of epidural analgesia, can be avoided or treated by left
terine displacement and careful infusion of crystalloid and
asoconstrictors, without a chronotropic effect. Hemody-
amic monitoring during labor and delivery with a pulmo-
ary artery catheter is recommended in all patients with
oderate and severe MS (55). Optimization of left atrial
ressure before delivery may be needed and can be achieved
y diuresis and reduction of heart rate with beta-blockers.
ncreased venous return in the early puerperium may result
n a marked increase in left atrial and pulmonary pressure
56) and can lead to the development of pulmonary edema
6,7,18). For this reason, hemodynamic monitoring should
ontinue for 12 to 24 h after the delivery. The use of
ocolytic agents with beta-mimetic effect is contraindicated
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July 19, 2005:223–30 Valvular Heart Disease and Pregnancyn patients with MS because of their strong chronotropic
ffect (57), and the use of magnesium sulfate, which has
egligible hemodynamic effect, is preferred.
R. Mitral regurgitation during pregnancy is usually due
o rheumatic valvular disease or mitral valve prolapse
6,18,20). Because of the significant fall in systemic vascular
esistance during pregnancy and reduced left ventricular
fterload (9), MR is well tolerated even if severe. For the
atient with MR who is contemplating pregnancy, but is
ot considered a candidate for surgical mitral valve repair or
eplacement on the basis of usual clinical indications (58),
rophylactic surgery should not be done, because pregnancy
fter valve replacement may be less desirable. Asymptomatic
atients do not require therapy during pregnancy, and the
reatment of patients with left ventricular dysfunction who
evelop hemodynamic abnormalities and symptoms of heart
ailure can include the use of diuretics and digoxin. Because
ngiotensin-converting enzyme (ACE) inhibitors or angio-
ensin receptor antagonists are contraindicated during preg-
ancy (59), organic nitrates and hydralazine can be used for
asodilation. Because of the high incidence of fetal loss (52),
urgery for mitral valve repair or replacement should be
voided if possible during pregnancy and considered only in
atients with severe symptoms not controlled by medical
herapy.
ortic stenosis. Aortic stenosis (AS) during pregnancy is
ostly due to congenital etiology (2). Rheumatic AS is less
ommon and occurs in conjunction with mitral valve disease
n approximately 5% of pregnant women with rheumatic
alvular disease (1,6,18). Cases with subvalvular and supra-
alvular AS have also been described in pregnancy (60,61).
ost patients with mild and moderate AS have a favorable
utcome of pregnancy (6,61); at the same time, however,
he presence of severe AS may result in hemodynamic and
ymptomatic deterioration with the development of heart
ailure, leading to hospitalizations and premature delivery.
ilverside et al. (61) recently reported on 49 pregnancies in
9 women with congenital AS, more than one-half with
evere AS, and most of them asymptomatic before preg-
ancy. Early cardiac complications, including pulmonary
dema and atrial arrhythmias, occurred in three pregnancies;
ne of them with severe AS (aortic valve area 0.5 cm2, peak
radient 112 mm Hg) required urgent percutaneous aortic
alvuloplasty at 12 weeks’ gestation. Rate of cardiac mor-
idity during pregnancy, as well as cardiac surgery at
ollow-up after pregnancy, was related to severity of AS,
ith cardiac complications occurring in 10% of patients
ith severe AS, compared with none in mild or moderate
S. Six pregnancies were associated with adverse fetal
vent, which included prematurity (8%), small for gesta-
ional age (2%), and neonatal distress respiratory syndrome
6%). In addition, 31% of the patients underwent surgery
uring a follow-up period of 2.6  2 years after the index
regnancy. Hameed et al. (6) reported on 12 pregnancies in
2 women with predominant AS. There was a higher
ncidence of maternal complications in patients with mod- prate and severe AS compared with their individually
atched normal control subjects, with congestive heart
ailure reported in 44% of patients, arrhythmias in 25%,
eed to commence or increase cardiac medications in 33%,
nd hospitalizations in 33%. Fetal outcome was also affected
y the presence of moderate and severe AS with higher
ncidence of preterm birth (44%), intrauterine growth re-
ardation (22%), and lower birth weight (2,650  987 g, vs.
,391  412 g, p  0.002). In spite of increased incidence
f morbidity, mortality was limited to only 1 of 61 preg-
ancies in patients with AS reported in the above two
tudies (6,61). This patient had severe AS in addition to a
oarctation of the aorta and died in conjunction with aortic
alve replacement 10 days after a successful abdominal
elivery.
In summary, most patients with AS, especially those with
alve area 1.0 cm2, tolerate pregnancy well, provided early
iagnosis and close follow-up. Severe AS can be associated
ith important maternal morbidity and unfavorable fetal
utcome, but maternal mortality is rare. In addition, a high
ate of expected cardiac surgery after the pregnancy in
omen with severe AS should be taken into account and
xplained to the patients at the time of pre-pregnancy
ounseling (61). Ideally, women with severe AS should
ndergo either balloon valvuloplasty, if appropriate, or valve
eplacement before pregnancy. The medical treatment in
ymptomatic patients with AS during gestation is limited to
iuretics. Patients who develop severe symptoms during
regnancy, but are resistant to medical therapy and cannot
e delivered, may require early termination of pregnancy
60) or repair of the valve either by percutaneous balloon
alvuloplasty (61–63) or surgery (64). Because balloon
alvuloplasty seems to be associated with a smaller risk of
etal loss compared with surgical replacement (52), valvulo-
lasty is preferred when possible. Both interventions carry
isk to the fetus (radiation with valvuloplasty and fetal loss
ith surgery), and complaints related to pregnancy itself can
imic cardiac disease; therefore, symptoms should be care-
ully evaluated before the decision to perform these proce-
ures is made. When intervention seems to be indicated and
etal maturity can be confirmed, the patient should be
elivered first and valve repair or replacement should be
erformed after delivery if possible. Hemodynamic moni-
oring is strongly recommended for labor and delivery in
atients with moderate and severe AS. The preferred mode
f delivery is vaginal with assisted second stage of labor.
aginal delivery was performed successfully in 67% of 49
regnancies in women with AS reported by Silversides et al.
61); two-thirds of these patients had labor induced. Cesarean
elivery was performed in 33% of the patients, but only in one
ase due to maternal cardiac indication. Regional anesthesia for
abor and delivery should be used with caution in patients with
S to prevent a decrease in systemic vascular resistance
hat may be poorly tolerated, and general anesthesia
emains the preferred technique for cesarean section in
atients with AS (53).
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Valvular Heart Disease and Pregnancy July 19, 2005:223–30ortic regurgitation. Aortic regurgitation (AR) in young
omen may be due to congenital bicuspid valve (2,61),
heumatic disease (6), endocarditis (65), or dilated aortic
nnulus (66). Similar to MR, AR without left ventricular
ysfunction is usually well tolerated during pregnancy,
robably secondary to a marked fall in systemic vascular
esistance and possibly due to the physiological increase in
eart rate which may shorten diastolic and thus reduce
egree of regurgitation (9). In cases of severe AR and left
entricular dysfunction that are symptomatic, medical ther-
py can include salt restriction, diuretics, and digoxin. The
asodilators hydralazine and nitrates can be used as a
ubstitute to ACE inhibitors, which are contraindicated
uring pregnancy (59). Surgery, if indicated, should be
elayed if possible until after the delivery to avoid the
igh risk of fetal loss (52). Symptomatic patients and
atients with left ventricular dysfunction should benefit
rom hemodynamic monitoring during labor and deliv-
ry. Asymptomatic patients with severe AR, but normal
eft ventricular function who contemplate pregnancy and
re not considered candidates for valve replacement on
he basis of established indications (58) will do well and
hould not have prophylactic valve surgery before
regnancy.
ulmonic stenosis. Isolated pulmonic stenosis (PS) dur-
ng pregnancy is most commonly due to a congenital
bstruction at the valvular level but can also occur at the
ubvalvular or supravalvular level and as a consequence of
eterioration of a homograft inserted as part of the Ross
rocedure (2,67).
Isolated valvular PS, even when severe, is usually well
olerated during pregnancy. An early study by Nielson et al.
68) reported on 26 pregnancies in 11 patients with PS.
here were four spontaneous abortions, one in a patient
ith severe PS who had right heart failure during the first
regnancy but then had three additional uneventful preg-
ancies after valvotomy. More recently, Hameed et al. (69)
eported the outcome of pregnancy in 17 patients with PS
rom 1995 to 2003. Eleven patients were in NYHA func-
ional class I, and six in class II at the time of presentation.
ll patients remained stable during pregnancy except one
ho deteriorated from class I to III early during preg-
ancy, but then improved to class II as pregnancy
rogressed. There was no difference between patients and
heir matched control subjects in duration of pregnancy
38.4  1.9 weeks vs. 39.3  1.2 weeks, p  0.07), birth
eight (3,278  474 g vs. 3,360  432 g, p  0.83), or
lacental weight (648  184 g vs. 693  421 g, p 
.83). Average Apgar scores at one min and five min were
ine for each group. A comparison between patients with
evere PS (peak gradient across the value 50 mm Hg
ith a mean of 82  28 mm Hg) and those with milder
S (mean gradient 34  11 mm Hg) revealed no
ifference in any of the studied parameters. In spite of the
imited number of patients with PS reported, the avail-
ble information indicates that pregnancy in patientsith PS is tolerated well and that, in contrast to MS and
S, the severity of PS does not adversely impact maternal
r fetal outcome. Balloon valvuloplasty is recommended
n non-pregnant patients when the gradient across the
ight ventricular outflow track is 50 mm Hg at rest (70)
r when the patient is symptomatic. Such a procedure,
owever, is rarely indicated during pregnancy in patients
ho are either asymptomatic or mildly symptomatic
efore pregnancy. Vaginal delivery is tolerated well and
an be permitted in the great majority of patients with
S.
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